Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
出版年份 2022 全文链接
标题
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 40, Issue 29, Pages 3365-3376
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2022-08-27
DOI
10.1200/jco.22.01002
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
- (2022) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.
- (2021) Frederik Marmé et al. JOURNAL OF CLINICAL ONCOLOGY
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
- (2020) Richard S. Finn et al. BREAST CANCER RESEARCH AND TREATMENT
- Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
- (2020) K. Kalinsky et al. ANNALS OF ONCOLOGY
- Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial
- (2019) Peng Yuan et al. EUROPEAN JOURNAL OF CANCER
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
- (2019) M.E. Cazzaniga et al. BREAST
- CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
- (2019) Jennifer J Gao et al. LANCET ONCOLOGY
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
- (2018) David M. Goldenberg et al. Oncotarget
- Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
- (2016) X. Pivot et al. ANNALS OF ONCOLOGY
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
- (2016) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2015) Peter A. Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Trop-2 Is a Determinant of Breast Cancer Survival
- (2014) Federico Ambrogi et al. PLoS One
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More